Gadicke Ansbert's Form 4 filing
Entrada Therapeutics, Inc. (TRDA) · filed Sep 9, 2026
- Accession no.
- 0001231919-26-001155
- Filed
- Sep 9, 2026, 7:23 PM ET
- Trade date
- Sep 4-9, 2026
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $1.91M. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gadicke AnsbertCIK 0001134655 | 10% Owner |
| Evnin LukeCIK 0001134657 | 10% Owner |
| Foley ToddCIK 0001473930 | 10% Owner |
| MPM BioVentures 2014, L.P.CIK 0001609492 | 10% Owner |
| MPM BioVentures 2014 (B), L.P.CIK 0001609493 | 10% Owner |
| MPM Asset Management Investors BV2014 LLCCIK 0001609495 | 10% Owner |
| MPM Bioventures 2018 (B), L.P.CIK 0001729504 | 10% Owner |
| MPM Asset Management Investors BV2018 LLCCIK 0001734817 | 10% Owner |
| MPM BioVentures 2014 LLCCIK 0001765021 | 10% Owner |
| MPM BioVentures 2014 GP LLCCIK 0001765091 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 4, 2026 | Common Stock | SSaleDisposed | −38,500 | $7.11F2 | −$273,735 | 4,106,452 | Indirect | |
| Sep 8, 2026 | Common Stock | SSaleDisposed | −192,500 | $7.41F6 | −$1,426,425 | 3,913,952 | Indirect | |
| Sep 9, 2026 | Common Stock | SSaleDisposed | −28,837 | $7.13F9 | −$205,607.81 | 3,885,115 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.01 to $7.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Referenced by the price of 1 transaction in Table I.
- F6
Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Referenced by the price of 1 transaction in Table I.
- F9
Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.02 to $7.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Referenced by the price of 1 transaction in Table I.
Remarks
See Form 4 for MPM BioVentures 2018, L.P for additional members of this joint filing.